Deal title |
Principal |
Partner |
Total projected at signing (US$M) |
Start date |
May | ||||
Abbvie to settle patent litigation with BI for intellectual property related to Humira in the U.S. |
Abbvie Inc. |
Boehringer Ingelheim International GmbH |
Payment unspecified |
5/14/19 |
Abcellera to develop a platform capable of creating field-ready medical countermeasures within 60 days of a pandemic viral outbreak using Ichor's Trigrid electroporation-mediated nucleic acid administration platform |
Abcellera Biologics Inc. |
Ichor Medical Systems Inc. |
Payment unspecified |
5/10/19 |
Accredo to supply Titan Pharmaceuticals' Probuphine for opioid use disorder in the U.S. |
Accredo Health Group Inc. |
Titan Pharmaceuticals Inc. |
Payment unspecified |
5/13/19 |
Forty Seven and Acerta Pharma to evaluate immune oncology triple combination drug in diffuse large B cell lymphoma |
Acerta Pharma BV |
Forty Seven Inc. |
Payment unspecified |
5/10/19 |
Nordic Bioscience to evaluate AKL Research and Development's Appa for osteoarthritis |
AKL Research and Development Ltd. |
Nordic Bioscience A/S |
Payment unspecified |
5/2/19 |
Adaptimmune and Alpine Immune Sciences to develop next-generation human induced pluripotent stem cell-derived allogeneic specific peptide enhanced affinity receptor T-cell products for cancer, with an option for worldwide rights |
Alpine Immune Sciences Inc. |
Adaptimmune Therapeutics plc |
$290.00 |
5/14/19 |
Altasciences to provide safety testing, IND enabling study and clinical trial services for Leidos' RAP-103 peptide |
Altasciences Clinical Research |
Leidos Inc. |
Payment unspecified |
5/22/19 |
ACTC and Eisai to evaluate BAN-2401 for Alzheimer's disease |
Alzheimer's Clinical Trials Consortium |
Eisai Co. Ltd. |
Payment unspecified |
5/10/19 |
Boehringer to evaluate a phase Ib (KISIMA-01) study of Amal Therapeutics' ATP-128 in combination with BI-754091 against stage IV colorectal cancer |
Amal Therapeutics SA |
Boehringer Ingelheim International GmbH |
Payment unspecified |
5/2/19 |
Lupin to market Aptissen's products in Canada |
Aptissen SA |
Lupin Ltd. |
Payment unspecified |
5/9/19 |
Intelgenx and Aquestive to co-develop tadalafil oral films for erectile dysfunction worldwide |
Aquestive Therapeutics Inc. |
Intelgenx Technologies Corp. |
Payment unspecified |
5/8/19 |
Modulus to use Astellas' drug discovery data for small molecule discovery |
Astellas Pharma Inc. |
Modulus Discovery Inc. |
Payment unspecified |
5/30/19 |
Astrazeneca and Sensei to conduct two phase II combination studies of SNS-301 with Imfinzi in head and neck cancer patients |
Astrazeneca plc |
Sensei Biotherapeutics Inc. |
Payment unspecified |
5/7/19 |
Medicago to use Atum's Genegps technology for development of virus-like particle vaccine and antibody therapeutics |
Atum |
Medicago Inc. |
Payment unspecified |
5/28/19 |
Aurora Cannabis and UFC to advance clinical research on hemp derived cannabidiol products for pain, inflammation and injury |
Aurora Cannabis Inc. |
Ultimate Fighting Championship |
Payment unspecified |
5/21/19 |
Be The Match Biotherapies to provide end-to-end support services for clinical development of Poseida's BCMA and PSMA chimeric antigen receptor T cell programs |
Be The Match Biotherapies |
Poseida Therapeutics Inc. |
Payment unspecified |
5/14/19 |
Be The Match to support phase III clinical studies of Kiadis' ATIR-101 as an adjunctive treatment in haploidentical hematopoietic stem cell transplantation for blood cancer |
Be The Match Biotherapies |
Kiadis Pharma Netherlands BV |
Payment unspecified |
5/22/19 |
Verve Therapeutics to access Beam Therapeutics' base editing, gene editing and delivery technologies for human therapeutic applications against certain cardiovascular targets |
Beam Therapeutics |
Verve Therapeutics Inc. |
Payment unspecified |
5/7/19 |
Neuraxpharm to market Bened Biomedical's PS-128 for central nervous system disorders in Europe |
Bened Biomedical Co. Ltd. |
Neuraxpharm Arzneimittel GmbH and Co. |
Payment unspecified |
5/28/19 |
Astrazeneca and Benevolentai to use artificial intelligence and machine learning to develop treatments against chronic kidney disease and idiopathic pulmonary fibrosis |
Benevolentai Ltd. |
Astrazeneca plc |
Payment unspecified |
5/1/19 |
Beam and Bio Palette to cross-license intellectual property rights of genome-based editing technologies to develop human and microbiome-related therapeutics |
Bio Palette Co. Ltd. |
Beam Therapeutics |
Payment unspecified |
5/31/19 |
Biotem and Calixar to develop therapeutic antibodies against membrane targets |
Biotem |
Calixar |
Payment unspecified |
5/20/19 |
Caris to develop companion diagnostic for Debiopharm to detect rare FGFR fusions using molecular intelligence transcriptome to evaluate Debio-1347 in patients for a phase II trial against solid tumor |
Caris Life Sciences |
Debiopharm SA |
Payment unspecified |
5/30/19 |
Eli Lilly to develop and commercialize Centrexion's CNTX-0290 for chronic pain worldwide |
Centrexion Therapeutics Corp. |
Eli Lilly and Co. |
$997.50 |
5/28/19 |
Novartis to use Codexis' Codeevolver protein engineering platform to develop performance enzymes |
Codexis Inc. |
Novartis AG |
Payment unspecified |
5/15/19 |
Westmed Medical and Columbia Care to study the therapeutic effectiveness and safety of medical cannabis as a pain reliever in rheumatologic patients with inflammatory arthritis |
Columbia Care LLC |
Westmed Medical Group |
Payment unspecified |
5/21/19 |
Corerx to manufacture and supply Aimmune's AR-101 against peanut allergy |
Corerx Inc. |
Aimmune Therapeutics Inc. |
Payment unspecified |
5/14/19 |
Aslan to develop and commercialize CSL's ASLAN-004 for atopic dermatitis worldwide |
CSL Ltd. |
Aslan Pharmaceuticals Pte Ltd. |
$780.00 |
5/31/19 |
Takeda to develop Curadev's CRD-5500 for cancer |
Curadev Pharma Pvt. Ltd. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
5/8/19 |
Meroven to market and distribute Cure Pharmaceutical's Spee-D in the U.S. |
Cure Pharmaceutical Holding Corp. |
Meroven LLC |
Payment unspecified |
5/3/19 |
Denovium to combine artificial intelligence platform with Maxygen's molecular breeding technology for protein engineering |
Denovium Inc. |
Maxygen LLC |
Payment unspecified |
5/22/19 |
Dyadic and Alphazyme to develop medicines and diagnostic tools using gene expression platform |
Dyadic International Inc. |
Alphazyme LLC |
Payment unspecified |
5/6/19 |
Dyadic and Serum Institute to develop and manufacture twelve antibodies and vaccine using C1 gene expression platform |
Dyadic International Inc. |
Serum Institute of India Ltd. |
Payment unspecified |
5/7/19 |
Anji Pharmaceuticals acquires worldwide development rights for Metformin DR from Elcelyx Therapeutics against type II diabetes patients with chronic kidney disease |
Elcelyx Therapeutics Inc. |
Anji Pharmaceuticals Inc. |
Payment unspecified |
5/29/19 |
Eurofins to provide genetic biomarker testing to support Adial's AD-04 phase III clinical trial for alcohol use disorder |
Eurofins Scientific |
Adial Pharmaceuticals LLC |
Payment unspecified |
5/7/19 |
ASC Therapeutics to use Expression Therapeutics' critical technologies for hemophilia A gene therapy |
Expression Therapeutics LLC |
ASC Therapeutics |
Payment unspecified |
5/16/19 |
Valirx to acquire worldwide granted patents and intellectual property assets from FIT Biotech |
FIT Biotech Oyj plc |
Valirx plc |
$0.01 |
5/2/19 |
Bayer and Foundation Medicine to develop and commercialize next generation sequencing-based companion diagnostics for Vitrakvi and other cancer therapies worldwide |
Foundation Medicine Inc. |
Bayer AG |
Payment unspecified |
5/29/19 |
FSD Pharma and Solarvest Bioenergy to develop algae-based pharmaceutical grade cannabinoids |
FSD Pharma Inc. |
Solarvest Bioenergy Inc. |
$1.00 |
5/7/19 |
Oncosec to acquire Gaeta Therapeutics' patents and applications related to combination of IL-12 DNA and checkpoint inhibitor therapies against cancer worldwide |
Gaeta Therapeutics Ltd. |
Oncosec Medical Inc. |
Payment unspecified |
5/22/19 |
Genocea to evaluate Iovance's tumor-infiltrating lymphocyte products using its neoantigen identification platform, Atlas platform |
Genocea Biosciences Inc. |
Iovance Biotherapeutics Inc. |
Payment unspecified |
5/15/19 |
Gilead Sciences and Goldfinch Bio to discover, develop and commercialize new therapies for diabetic kidney disease and orphan kidney disease |
Goldfinch Bio Inc. |
Gilead Sciences Inc. |
$2,059.00 |
5/8/19 |
Boehringer Ingelheim and Gubra to develop poly-agonist peptides for obesity |
Gubra Aps |
Boehringer Ingelheim International GmbH |
$272.51 |
5/29/19 |
An undisclosed pharmaceutical company to use Harbour Biomed's HCAb transgenic mouse platform to discover, develop and commercialize antibodies against cancer |
Harbour Biomed Ltd. |
Undisclosed Pharmaceutical Company |
Payment unspecified |
5/28/19 |
Harbour Biomed and Chia Tai Tianqing to discover, develop and commercialize biologics for multiple therapeutic targets in oncology and immunology in multiple territories |
Harbour Biomed Ltd. |
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. |
Payment unspecified |
5/5/19 |
Medavate to acquire Neocart assets from Histogenics |
Histogenics Corp. |
Medavate Corp. |
$6.50 |
5/8/19 |
Huons and Genexine to sign memorandum of understanding to develop therapeutics for rare diseases |
Huons Co. Ltd. |
Genexine Co. Ltd. |
Payment unspecified |
5/17/19 |
Exelixis and Iconic Therapeutics to develop an antibody drug conjugate program for cancer and an option to license ICON-2 |
Iconic Therapeutics Inc. |
Exelixis Inc. |
$7.50 |
5/16/19 |
Ilera and Ethicann to develop and manufacture botanical THC against chemotherapy induced nausea and vomiting |
Ilera Healthcare |
Ethicann Pharmaceuticals Inc. |
Payment unspecified |
5/22/19 |
A privately held biotechnology company to acquire Immunocellular's ICT-107, ICT-121, ICT-140 clinical and preclinical programs, intellectual property, technology and know-how |
Immunocellular Therapeutics Ltd. |
Undisclosed |
$1.00 |
5/8/19 |
HLS Therapeutics to commercialize Indivior's Perseris for schizophrenia in Canada |
Indivior plc |
HLS Therapeutics Inc. |
$5.00 |
5/9/19 |
Chiesi Farmaceutici to acquire an option to develop and commercialize Inhibrx's INBRX-101 outside of the U.S. and Canada for alpha-1 antitrypsin deficiency |
Inhibrx LLC |
Chiesi Farmaceutici SpA |
$172.50 |
5/30/19 |
Innovation and undisclosed pharmaceutical company to sign non-binding term sheet to develop and commercialize Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis worldwide |
Innovation Pharmaceuticals Inc. |
Undisclosed |
Payment unspecified |
5/16/19 |
Merck to explore Intec Pharma's accordion pill drug delivery platform for an undisclosed program |
Intec Pharma Ltd. |
Merck & Co. Inc. |
Payment unspecified |
5/16/19 |
Myungmoon Pharm to commercialize Kerastem's hair growth therapy in South Korea, China and ASEAN member states |
Kerastem Technologies |
Myungmoon Pharm Co. Ltd. |
$140.00 |
5/14/19 |
Kite Pharma to evaluate Yescarta with Humanigen's Lenzilumab in phase I/II study in patients with relapsed or refractory diffuse large B-cell lymphoma |
Kite Pharma Inc. |
Humanigen Inc. |
Payment unspecified |
5/31/19 |
Kymera and Vertex to discover and develop small molecule protein degraders using Pegasus drug discovery platform for multiple targets |
Kymera Therapeutics LLC |
Vertex Pharmaceuticals Inc. |
$1,070.00 |
5/15/19 |
Motif Bio to assess delivery of LMS-611 with Lamellar Biomedical's lamellasome technology for cystic fibrosis |
Lamellar Biomedical Ltd. |
Motif Bio plc |
Payment unspecified |
5/1/19 |
Cumulus Oncology to develop and commercialize Ligand Pharmaceuticals' VER-250840 for cancer worldwide |
Ligand Pharmaceuticals Inc. |
Cumulus Oncology Ltd. |
$76.00 |
5/17/19 |
Lonza to manufacture and supply Chiasma's Mycapssa for acromegaly |
Lonza Group AG |
Chiasma Inc. |
Payment unspecified |
5/14/19 |
Biontech acquires Mabvax Therapeutics' MVT-5873 and other preclinical antibody assets |
Mabvax Therapeutics Holdings Inc. |
Biontech SE |
Payment unspecified |
5/8/19 |
Australasian Medical to market and distribute Mannkind's Afrezza inhalation powder for diabetes in Australia |
Mannkind Corp. |
Australasian Medical and Scientific Ltd. |
Payment unspecified |
5/16/19 |
Eisai to commercialize Medac's methotrexate injection for rheumatoid arthritis in Japan |
Medac GmbH |
Eisai Co. Ltd. |
Payment unspecified |
5/10/19 |
Vericel to commercialize Mediwound's Nexobrid in North America for burn care |
Mediwound Ltd. |
Vericel Corp. |
$150.00 |
5/6/19 |
14ner Oncology to purchase Merrimack's MM-121 and MM-111 for various cancers |
Merrimack Pharmaceuticals Inc. |
14ner Oncology Inc. |
$58.00 |
5/28/19 |
Grow Biotech to distribute MGC Pharma's Cannepil for epilepsy and Cognicann for dementia and Alzheimer's disease in U.K. |
MGC Pharma |
Grow Biotech plc |
Payment unspecified |
5/6/19 |
Biosyent to commercialize Mithra's Tibelia for postmenopausal osteoporosis in Canada |
Mithra Pharmaceuticals |
Biosyent Inc. |
Payment unspecified |
5/20/19 |
Hormosan to commercialize Mithra's Myring for contraception in Germany |
Mithra Pharmaceuticals |
Hormosan Kwizda GmbH |
Payment unspecified |
5/28/19 |
Molteni to distribute Shionogi's Rizmoic for opioid-induced constipation in Italy and Poland |
Molteni Farmaceutici |
Shionogi and Co. Ltd. |
Payment unspecified |
5/22/19 |
Kyorin to enter into a memorandum of understanding to co-market MSD Japan's MK-7264 for chronic cough in Japan |
MSD Japan |
Kyorin Holdings Inc. |
Payment unspecified |
5/13/19 |
Pneuma Respiratory to develop Leads Biolabs' monoclonal antibodies and fusion protein molecules for pulmonary delivery against oncologic or immune-mediated lung diseases |
Nanjing Leads Biolabs Co. Ltd. |
Pneuma Respiratory Inc. |
Payment unspecified |
5/15/19 |
Lantheus to develop and commercialize Nanomab Technology's NM-01 biomarker for clinical development and management of immuno-oncology therapies |
Nanomab Technology Ltd. |
Lantheus Medical Imaging Inc. |
Payment unspecified |
5/30/19 |
Sumitomo Dainippon and Novartis Pharma to co-promote and sell Equa 50mg tablets and Equmet combination LD/HD tablets for type 2 diabetes in Japan |
Novartis Pharma KK |
Sumitomo Dainippon Pharma Co. Ltd. |
Payment unspecified |
5/30/19 |
Santen extend the 2017 agreement to distribute NTC's levofloxacin/dexamethasone fixed combination eye drops for cataract in Vietnam, Thailand, Singapore, Malaysia, Philippines, Indonesia, Myanmar, Hong Kong, Macau, Brunei, Laos, Cambodia, Sri Lanka, Bangladesh and Pakistan |
NTC Srl |
Santen Pharmaceutical Co. Ltd. |
Payment unspecified |
5/23/19 |
Cstone Pharmaceuticals to develop and commercialize Numab Therapeutics' ND-021 for cancer in greater China, including mainland China, Hong Kong, Macau and Taiwan, South Korea and Singapore |
Numab Therapeutics AG |
Cstone Pharmaceuticals Co. Ltd. |
Payment unspecified |
5/1/19 |
Hanx to develop and commercialize Onconova's Rigosertib for the treatment of higher-risk myelodysplastic syndromes in greater China |
Onconova Therapeutics Inc. |
Hanx Biopharmaceuticals Inc. |
$51.50 |
5/13/19 |
Emerge Health to commercialize Oncosec's Tavo for refractory metastatic melanoma in Australia |
Oncosec Medical Inc. |
Emerge Health Pty Ltd. |
Payment unspecified |
5/29/19 |
Primo Trading to distribute and commercialize Optibiotix's Slimbiome for weight loss in the Thailand |
Optibiotix Health plc |
Primo Trading Co. Ltd. |
Payment unspecified |
5/14/19 |
Gene Techno Science and Orthorebirth to develop therapeutics for cleft lip or cleft palate |
Orthorebirth Co. Ltd. |
Gene Techno Science Co. Ltd. |
Payment unspecified |
5/10/19 |
Otonomy to co-promote Glenmark's Otiprio for acute otitis externa in the U.S. |
Otonomy Inc. |
Glenmark Therapeutics Inc. |
Payment unspecified |
5/2/19 |
Oxford Genetics and CGT Catapult to develop scalable lentiviral manufacturing processes |
Oxford Genetics Ltd. |
Cell and Gene Therapy Catapult |
Payment unspecified |
5/13/19 |
Genentech to develop and commercialize Parvus' Navacim therapeutics against inflammatory bowel disease, autoimmune liver diseases and celiac disease worldwide |
Parvus Therapeutics Inc. |
Genentech Inc. |
$800.00 |
5/16/19 |
Patheon Biologics to produce Cantargia's CAN-04 for pancreatic and non-small-cell lung cancers |
Patheon Biologics BV |
Cantargia AB |
Payment unspecified |
5/13/19 |
Pentapharm and Simcere to jointly develop and commercialize Defibrase in China |
Pentapharm AG |
Simcere Pharmaceutical Group |
Payment unspecified |
5/27/19 |
FLX Bio to use Personalis' Immunoid Next to evaluate FLX-475 or in combination with pembrolizumab against cancer |
Personalis Inc. |
FLX Bio Inc. |
Payment unspecified |
5/20/19 |
Biocure Pharm and Pharos Vaccine to develop anti-CD19 chimeric antigen receptor T-cell therapy products for leukemia and lymphoma worldwide, except China |
Pharos Vaccine Inc. |
Biocure Pharm Corp. |
Payment unspecified |
5/17/19 |
Panaxia and Plantext to co-develop medical cannabis products for inflammatory bowel disease, Crohn's disease and colitis |
Plantext Ltd. |
Panaxia Pharmaceutical Industries Ltd. |
Payment unspecified |
5/1/19 |
Presage Biosciences to evaluate Celgene's early stage assets in phase 0 trials and patient responses to microdoses of multiple cancer drugs using Presage's Civo platform |
Presage Biosciences Inc. |
Celgene Corp. |
Payment unspecified |
5/2/19 |
Vaccitech to use Probiogen's AGE1.CR duck retina cell line technology to produce viral vectored vaccines, including VTP-100 |
Probiogen AG |
Vaccitech Ltd. |
Payment unspecified |
5/15/19 |
Rotop to develop and commercialize Progenics' imaging agent, 1404 against prostate cancer in Europe |
Progenics Pharmaceuticals Inc. |
Rotop Pharmaka GmbH |
Payment unspecified |
5/14/19 |
Prolynx and Daiichi Sankyo to use drug delivery linker technology to extend the intravitreal half-life of Daiichi's candidates |
Prolynx LLC |
Daiichi Sankyo Co. Ltd. |
Payment unspecified |
5/3/19 |
Qiagen and Inovio to co-develop liquid biopsy-based precision medicine test for VGX-3100 to treat precancerous cervical lesions |
Qiagen NV |
Inovio Pharmaceuticals Inc. |
Payment unspecified |
5/16/19 |
Reform Biologics to conduct feasibility studies to enhance the formulation of Bayer's two clinical-stage programs |
Reform Biologics LLC |
Bayer AG |
Payment unspecified |
5/14/19 |
Cincor to develop and commercialize Roche's CIN-107 for resistant hypertension and primary aldosteronism worldwide |
Roche Holding AG |
Cincor Pharma Inc. |
Payment unspecified |
5/14/19 |
Chiesi to develop Santhera's Raxone for Leber's hereditary optic neuropathy and all other ophthalmological indications worldwide, except the U.S. and Canada |
Santhera Pharmaceuticals AG |
Chiesi Farmaceutici SpA |
$105.33 |
5/23/19 |
Bayer to use Sensible Medical Innovations' Reds technology in a clinical trial to study the efficacy of BAY-1753011 |
Sensible Medical Innovations Ltd. |
Bayer AG |
Payment unspecified |
5/28/19 |
Meridian to commercialize Siga Technologies' oral Tpoxx for smallpox worldwide except for the U.S. and South Korea |
Siga Technologies Inc. |
Meridian Medical Technologies Inc. |
Payment unspecified |
5/31/19 |
Skyhawk and Takeda to discover and develop RNA splicing modifiers for neurological diseases using Skystar technology worldwide |
Skyhawk Therapeutics Inc. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
5/6/19 |
Perrigo Israel to develop and commercialize Sol-Gel's generic antibiotic foams in the U.S. |
Sol-Gel Technologies Ltd. |
Perrigo Israel Agencies Ltd. |
Payment unspecified |
5/28/19 |
Arcus to use Strata's drug development platform and biomarkers for evaluation of AB-122 against cancers |
Strata Oncology |
Arcus Biosciences Inc. |
$2.50 |
5/2/19 |
Synlogic to evaluate combination of SYNB-1891 with Roche's atezolizumab for advanced solid tumors |
Synlogic Inc. |
Roche Holding AG |
Payment unspecified |
5/22/19 |
Novartis to acquire Takeda's Xiidra for dry eye disease worldwide |
Takeda Pharmaceutical Co. Ltd. |
Novartis AG |
$5,300.00 |
5/8/19 |
Ethicon to acquire Takeda's Tachosil for hemostasis |
Takeda Pharmaceutical Co. Ltd. |
Ethicon Inc. |
$400.00 |
5/8/19 |
Takeda Pharmaceuticals to spin out Phathom Pharmaceuticals to develop and commercialize therapeutics, including vonoprazan for acid-related gastrointestinal disorders in the U.S., Europe and Canada |
Takeda Pharmaceutical Co. Ltd. |
Phathom Pharmaceuticals Inc. |
Payment unspecified |
5/15/19 |
Bicycle Therapeutics and DDF to develop therapeutics using bicyclic peptide technology for neurodegenerative diseases, including dementia |
The Dementia Discovery Fund |
Bicycle Therapeutics Ltd. |
Payment unspecified |
5/7/19 |
Transgene and Astrazeneca to develop oncolytic vaccinia virus candidates using Invir.IO |
Transgene SA |
Astrazeneca plc |
$13.00 |
5/2/19 |
Trovagene to evaluate the efficacy of onvansertib in combination with Nektar's Onzeald for metastatic colorectal cancer |
Trovagene Inc. |
Nektar Therapeutics |
Payment unspecified |
5/23/19 |
Ubiquigent to provide small molecule libraries access to Dorian Therapeutics for development drugs against age-associated diseases |
Ubiquigent Ltd. |
Dorian Therapeutics Inc. |
Payment unspecified |
5/23/19 |
Valirx to sign letter of intent with Alpha Blue Ocean to form a genetic therapeutic and diagnostic based joint venture |
Valirx plc |
Alpha Blue Ocean Advisors Ltd. |
Payment unspecified |
5/2/19 |
Vectura to enter settlement for resolving litigation of U.S. sales of GSK's Breo Ellipta, Anoro Ellipta and Incruse Ellipta |
Vectura Group plc |
Glaxosmithkline plc |
$89.70 |
5/3/19 |
Verve to use Verily's nanoparticle screening platform to develop and optimize new gene editing delivery vehicles for cardiovascular diseases |
Verily Life Sciences LLC |
Verve Therapeutics Inc. |
Payment unspecified |
5/7/19 |
Hansoh to develop and commercialize Viela Bio's inebilizumab for neuromyelitis optica spectrum disorder and other inflammation/autoimmune and hematologic malignancy indications in China |
Viela Bio Inc. |
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. |
$220.00 |
5/28/19 |
Viiv Healthcare to evaluate Matinas Biopharma's lipid nanocrystal formulation of antiviral drug candidates |
Viiv Healthcare Ltd. |
Matinas Biopharma Holdings Inc. |
Payment unspecified |
5/15/19 |
Virogin Biotech and China National Biotec to form joint venture to commercialize oncolytic virotherapies |
Virogin Biotech Canada Ltd. |
China National Biotec Group |
Payment unspecified |
5/8/19 |
Ginkgo Bioworks acquires Warp Drive Bio's genome mining platform to discover and develop antibiotics for drug-resistant bacterial infections |
Warp Drive Bio |
Ginkgo Bioworks |
Payment unspecified |
5/15/19 |
Medigen and Zhongji 1 to develop cell therapy in Hong Kong |
Zhongji 1 International Medical Group |
Medigen Biotechnology Corp. |
Payment unspecified |
5/23/19 |
Hoth to enter into a non-binding term sheet to co-develop Zylo's anandamide loaded Z-pods for cutaneous lupus erythematosus |
Zylo Therapeutics LLC |
Hoth Therapeutics Inc. |
Payment unspecified |
5/14/19 |
Iconic to use Zymeworks' Zymelink antibody drug conjugate platform to develop ICON-2 Tissue Factor ADC against cancer worldwide |
Zymeworks Inc. |
Iconic Therapeutics Inc. |
Payment unspecified |
5/14/19 |
GSK expanded the 2016 agreement, valued at $908M, to gain further access to Zymeworks' Azymetric technology to develop bispecific and multifunctional therapeutics, paying $1.1B in total |
Zymeworks Inc. |
Glaxosmithkline plc |
$192.00 |
5/17/19 |
June | ||||
Gilead to use Abcellera's expertise in single-cell screening for the discovery of therapeutic antibody candidates against infectious diseases |
Abcellera Biologics Inc. |
Gilead Sciences Inc. |
Payment unspecified |
6/13/19 |
Alvotech and Abdi Ibrahim to develop and commercialize biosimilar against autoimmune disease in Turkey |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Alvotech |
Payment unspecified |
6/3/19 |
Zai Lab to use Ablexis' Alivamab mouse platform to discover, develop and commercialize antibody drug candidates |
Ablexis LLC |
Zai Lab Ltd. |
Payment unspecified |
6/3/19 |
Abveris and Tetragenetics to collaborate on the discovery of antibodies against ion channel targets |
Abveris Inc. |
Tetragenetics Inc. |
Payment unspecified |
6/4/19 |
Accord Healthcare to distribute Clinigen's Cardioxane and Savene in Poland as protectant during chemotherapy |
Accord Healthcare Inc. |
Clinigen Group plc |
Payment unspecified |
6/24/19 |
Qilu Antibiotics Pharmaceutical to purchase Achaogen's plazomicin greater China rights |
Achaogen Inc. |
Qilu Antibiotics Pharmaceutical Co. Ltd. |
Payment unspecified |
6/6/19 |
Cipla to purchase Achaogen's Zemdri worldwide rights excluding greater China |
Achaogen Inc. |
Cipla USA Inc. |
Payment unspecified |
6/6/19 |
Chia Tai and Akeso to form a joint venture to develop AK-105 against cancers |
Akeso Biopharma Inc. |
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. |
Payment unspecified |
6/17/19 |
Allele Biotechnology and Alpine Biotherapeutics to develop human induced pluripotent stem cell-derived cell therapy products against retinal diseases including vision loss |
Allele Biotechnology and Pharmaceuticals Inc. |
Alpine Biotherapeutics Corp. |
Payment unspecified |
6/12/19 |
Allergy to settle a litigation with Inflamax Research for disclosing inconclusive phase II study of Grass MATA MPL |
Allergy Therapeutics plc |
Inflamax Research Inc. |
$7.60 |
6/27/19 |
Tedor to use Altus' Flexitab technology to develop sustained release tablets in North America |
Altus Formulation Inc. |
Tedor Pharma Inc. |
Payment unspecified |
6/4/19 |
Shanghai Junshi Biosciences to develop and commercialize Anwita's AWT-008 for cancer in greater China |
Anwita Biosciences Inc. |
Shanghai Junshi Biosciences Co. Ltd. |
$76.50 |
6/24/19 |
Arvinas and Bayer to develop Protac targeted protein degraders using Protac technology for pharmaceutical use for human |
Arvinas Inc. |
Bayer AG |
$749.50 |
6/3/19 |
Otsuka acquires cefixime business from Astellas Pharma |
Astellas Pharma Inc. |
Otsuka Kagaku KK |
Payment unspecified |
6/4/19 |
Atomwise to screen Enamine's small molecule libraries for cancer using artificial intelligence-powered virtual drug screening |
Atomwise |
Enamine Ltd. |
Payment unspecified |
6/24/19 |
Avacta and Selexis to develop CHO cell line for manufacture AVA-004 against solid tumor |
Avacta Ltd. |
Selexis SA |
Payment unspecified |
6/20/19 |
Bayer and Cstone to evaluate CS-1001 in combination with regorafenib against multiple cancers including gastric cancer |
Bayer HealthCare Ltd. |
Cstone Pharmaceuticals Co. Ltd. |
Payment unspecified |
6/9/19 |
Beigene and Springworks to form joint venture, Mapkure to develop BGB-3245 for cancer |
Beigene Co. Ltd. |
Springworks Therapeutics Inc. |
Payment unspecified |
6/18/19 |
Beigene received $150M payment for termination of collaboration with Celgene for tislelizumab |
Beigene Ltd. |
Celgene Corp. |
$150.00 |
6/18/19 |
Abveris to use Berkeley's Beacon optofluidic platform for antibody discovery |
Berkeley Lights Inc. |
Abveris Inc. |
Payment unspecified |
6/17/19 |
Biocartis to develop and commercialize assays to support Kite's therapies for cancer |
Biocartis |
Kite Pharma Inc. |
Payment unspecified |
6/1/19 |
Everest Medicines to develop and commercialize Calliditas' Nefecon for IgA nephropathy in China, Hong Kong, Macau, Taiwan and Singapore |
Calliditas Therapeutics AB |
Everest Medicines |
$121.00 |
6/10/19 |
Gilead to develop and commercialize small molecule immuno-oncology therapies using Carna Biosciences' lipid kinase drug discovery technology worldwide |
Carna Biosciences Inc. |
Gilead Sciences Inc. |
$470.00 |
6/24/19 |
Catalent to manufacture adeno-associated virus vector for Iveric Bio's IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa and IC-200 for BEST1-related retinal diseases |
Catalent Inc. |
Iveric Bio Inc. |
Payment unspecified |
6/17/19 |
ANI acquires Coeptis Pharmaceuticals' seven development stage generic products |
Coeptis Pharmaceuticals Inc. |
ANI Pharmaceuticals Inc. |
$14.30 |
6/18/19 |
Vertex Pharmaceuticals to develop and commercialize Crispr Therapeutics' gene editing products for Duchenne muscular dystrophy and myotonic dystrophy type 1 worldwide |
Crispr Therapeutics AG |
Vertex Pharmaceuticals Inc. |
$1,000.00 |
6/6/19 |
Debiopharm and Ipsen extended the agreement through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets |
Debiopharm SA |
Ipsen SA |
Payment unspecified |
6/13/19 |
Zai Lab to develop Deciphera's ripretinib against gastrointestinal stromal tumors and other solid tumors in mainland China, Hong Kong, Macau and Taiwan |
Deciphera Pharmaceuticals LLC |
Zai Lab Ltd. |
$205.00 |
6/10/19 |
Dualogics and Y-Biologics to discover and develop cancer antibodies |
Dualogics LLC |
Y-Biologics Inc. |
Payment unspecified |
6/10/19 |
Eczacıbasi-Monrol to distribute Telix's TLX250-CDx for renal cell cancer in Turkey, Middle East and North Africa |
Eczacıbasi-Monrol |
Telix Pharmaceuticals Ltd. |
Payment unspecified |
6/13/19 |
Lannett to distribute Elite's generic Dantrolene capsules in the U.S. |
Elite Pharmaceuticals Inc. |
Lannett Co. Inc. |
Payment unspecified |
6/28/19 |
Ricoh and Elixirgen to develop innovative biomedical products and services for cell differentiation technology-based drug discovery |
Elixirgen Scientific LLC |
Ricoh Co. Ltd. |
Payment unspecified |
6/19/19 |
Sanofi to use Enable Injections' Enfuse platform to deliver subcutaneous therapeutics |
Enable Injections LLC |
Sanofi SA |
Payment unspecified |
6/3/19 |
Atlantic Healthcare to acquire worldwide rights to Endologic's renzapride for gastrointestinal motility disorders |
Endologic LLC |
Atlantic Healthcare plc |
$51.00 |
6/26/19 |
Bioneer to use ERS Genomics' Crispr/Cas9 genome editing technology to generate and commercialize human cell-based disease models |
ERS Genomics Ltd. |
Bioneer A/S |
Payment unspecified |
6/4/19 |
Erytech Pharma and SQZ Biotech to develop antigen-specific immune modulating therapies for multiple indications worldwide |
Erytech Pharma SA |
SQZ Biotechnologies Inc. |
$107.00 |
6/24/19 |
Eton Pharmaceuticals to grant U.S. rights of ET-105 to Aucta Pharmaceuticals for neurological disorders |
Eton Pharmaceuticals Inc. |
Aucta Pharmaceuticals Inc. |
$23.00 |
6/13/19 |
Alvogen to acquire portfolio of prescription and over the counter drugs of women's healthcare from Exeltis in Russia, Ukraine and Kazakhstan |
Exeltis USA Inc. |
Alvogen Inc. |
Payment unspecified |
6/11/19 |
Exscientia and GT Apeiron to develop drugs via new pathways against therapeutic targets, including oncology using artificial intelligence drug discovery platform |
Exscientia Co. Ltd. |
GT Apeiron Therapeutics |
Payment unspecified |
6/11/19 |
Ferrer to promote Shionogi's Rizmoic for opioid-induced constipation in Spain |
Ferrer Internacional SA |
Shionogi BV |
Payment unspecified |
6/11/19 |
Kissei to co-promote Ferring's desmopressin acetate for nocturnal polyuria in Japan |
Ferring Pharmaceuticals SA |
Kissei Pharmaceutical Co. Ltd. |
Payment unspecified |
6/18/19 |
FDB to manufacture and supply Outlook Therapeutics' ONS-5010 for the treatment of wet age-related macular degeneration |
Fujifilm Diosynth Biotechnologies |
Outlook Therapeutics Inc. |
Payment unspecified |
6/3/19 |
Terns to develop and commercialize Genfit's elafibranor for the treatment of primary biliary cholangitis and nonalcoholic steatohepatitis in greater China |
Genfit SA |
Terns Pharmaceuticals Inc. |
$228.00 |
6/24/19 |
Janssen obtains option to develop and commercialize Genmab's Hexabody-CD38 against multiple myeloma and diffuse large B-cell lymphoma worldwide |
Genmab A/S |
Janssen Biotech Inc. |
$275.00 |
6/11/19 |
Ginkgo Bioworks to accelerate the expansion and development of Synlogic's pipeline of synthetic biotic medicines |
Ginkgo Bioworks Inc. |
Synlogic Inc. |
$110.00 |
6/13/19 |
Stada Arzneimittel to acquire five skin care brands and one pediatric cough remedy from Glaxosmithkline in Europe |
Glaxosmithkline plc |
Stada Arzneimittel AG |
Payment unspecified |
6/7/19 |
Valneva to terminate agreement with GSK related to vaccines against Lyme disease and chikungunya |
Glaxosmithkline plc |
Valneva SE |
$18.00 |
6/24/19 |
Glenmark to promote, commercialize and distribute Novartis' Seebri, Onbrize and Ultibro for chronic obstructive pulmonary disease in Brazil |
Glenmark Farmaceutica |
Novartis AG |
Payment unspecified |
6/24/19 |
Harvest One Cannabis to supply Gencanna's Dream Water, Satipharm, and Livrelief in the U.S. and Europe |
Harvest One Cannabis Inc. |
Gencanna Global USA Inc. |
Payment unspecified |
6/4/19 |
Medovex and Rion to develop cell therapy for chronic obstructive pulmonary disease |
H-cyte Inc. |
Rion LLC |
Payment unspecified |
6/24/19 |
Healios and Dainippon adjusted the agreement to develop induced pluripotent stem cell-derived retinal pigment epithelial cells for age related macular degeneration and other eye diseases in Japan |
Healios K.K. |
Sumitomo Dainippon Pharma Co. Ltd. |
$9.23 |
6/14/19 |
Devonian Health to manufacture and extract Histapharm's botanical drug containing DAO and develop products for dermatological applications |
Histapharm Inc. |
Devonian Health Group Inc. |
Payment unspecified |
6/3/19 |
Hitgen to use its technology platform to discover small molecule leads against targets of interest to Gilead |
Hitgen Ltd. |
Gilead Sciences Inc. |
Payment unspecified |
6/3/19 |
Immunophotonics and CLS to conduct phase Ib/IIa study on IP-001 for solid tumor indications |
Immunophotonics Inc. |
Clinical Laserthermia Systems Ab |
Payment unspecified |
6/14/19 |
BDD pharma to develop Innovation's Brilacidin tablets for ulcerative colitis using Oralogik technology |
Innovation Pharmaceuticals Inc. |
BDD Pharma Ltd. |
Payment unspecified |
6/6/19 |
Intralytix and Ferring Pharmaceuticals to develop and commercialize bacteriophage-based drugs for women's health |
Intralytix Inc. |
Ferring Pharmaceuticals SA |
Payment unspecified |
6/17/19 |
Surterra to advance cannabinoid production using Intrexon's yeast fermentation platform worldwide |
Intrexon Corp. |
Surterra Wellness |
$145.00 |
6/18/19 |
Biomx licensed a set of bacterial targets from JSR to develop and commercialize phage therapies for primary sclerosing cholangitis |
JSR Corp. |
Biomx Ltd. |
Payment unspecified |
6/12/19 |
Just to design and develop manufacturing process for Teva's products |
Just Biotherapeutics Inc. |
Teva Pharmaceutical Industries Ltd. |
Payment unspecified |
6/28/19 |
Casi Pharmaceuticals to commercialize Juventas' anti-CD19 T-cell therapy, CNCT-19 for hematological malignancies worldwide |
Juventas Therapeutics Inc. |
Casi Pharmaceuticals Inc. |
$11.60 |
6/17/19 |
Leadxpro to discover small molecule membrane therapeutics for Astex's targets using cryo-EM |
Leadxpro AG |
Astex Pharmaceuticals Inc. |
Payment unspecified |
6/3/19 |
Linearx to provide multiple customized linear DNA amplicons to Evotec for research on neurodegenerative diseases |
Linearx Inc. |
Evotec SE |
Payment unspecified |
6/26/19 |
Lonza to manufacture Gamida Cell's omidubicel for hematologic malignancies |
Lonza Group Ltd. |
Gamida Cell Ltd. |
Payment unspecified |
6/20/19 |
Astellas to use Lpixel's Imacel for cell evaluation to conduct research on regenerative medicine and cell therapy |
Lpixel Inc. |
Astellas Pharma Inc. |
Payment unspecified |
6/4/19 |
Medincell and undisclosed company to develop mdc-ANG for central nervous system diseases |
Medincell SA |
Undisclosed |
Payment unspecified |
6/12/19 |
Intensity to conduct phase I/II clinical study of INT230-6 in combination with Merck's Keytruda for solid tumor including pancreatic, bile duct, squamous cell and non-microsatellite instability high colon cancers |
Merck & Co. Inc. |
Intensity Therapeutics Inc. |
Payment unspecified |
6/25/19 |
Mesoblast expanded the partnership with JCR Pharmaceuticals for the use of mesenchymal stem cells to treat neonatal hypoxic ischemic encephalopathy |
Mesoblast Ltd. |
JCR Pharmaceuticals Co. Ltd. |
Payment unspecified |
6/12/19 |
Momenta and Amphastar to settle patent litigation related to enoxaparin sodium injection |
Momenta Pharmaceuticals Inc. |
Amphastar Pharmaceuticals Inc. |
Payment unspecified |
6/18/19 |
Egis to distribute Mundipharma's Pelmeg for neutropenia in Central and Eastern Europe |
Mundipharma International Corp. Ltd. |
Egis Gyogyszergyar RT |
Payment unspecified |
6/14/19 |
Jiangsu Hengrui to develop and commercialize Mycovia's VT-1161 in China, including mainland China, Hong Kong, Macau and Taiwan, for recurrent vulvovaginal candidiasis, onychomycosis and invasive fungal infections |
Mycovia Pharmaceuticals Inc. |
Jiangsu Hengrui Medicine Co. Ltd. |
Payment unspecified |
6/17/19 |
Mytomorrows to provide support services for the supply of Immodulon's IMM-101 in Europe for cancer |
Mytomorrows |
Immodulon Therapeutics Ltd. |
Payment unspecified |
6/27/19 |
Nanolek to sign memorandum of intention to manufacture Sanofi Pasteur's Pentaxim for infectious diseases in Russia |
Nanolek LLC |
Sanofi SA |
Payment unspecified |
6/4/19 |
Atlas and Nano Medical to distribute nanotechnology products in Mexico, Latin America and Europe |
Nanomedical Systems Inc. |
Atlas Nanotech |
Payment unspecified |
6/27/19 |
EMD Serono to use Nebula's anonymized genomic data to develop drugs |
Nebula Genomics |
EMD Serono Inc. |
Payment unspecified |
6/11/19 |
Nordmark to manufacture and supply Vivus's Pancreaze for exocrine pancreatic insufficiency |
Nordmark Arzneimittel GmbH & Co. KG |
Vivus Inc. |
Payment unspecified |
6/25/19 |
Premark Pharma to develop and commercialize Novartis' PMP-2207 for blepharitis |
Novartis AG |
Premark Pharma GmbH |
Payment unspecified |
6/25/19 |
Sobi to acquire Novimmune's all assets relating to emapalumab in the field of immunology and an option to develop NI-1801 and NI-1701 in the field of immuno-oncology |
Novimmune SA |
Swedish Orphan Biovitrum AB |
$516.60 |
6/12/19 |
Undisclosed pharma company to enter agreement with Noxxon Pharma to evaluate NOX-A12 for a new indication |
Noxxon Pharma AG |
Undisclosed pharma company |
Payment unspecified |
6/24/19 |
Gilead and Nurix to discover, develop and commercialize E3 ligase modulating targeted protein degradation drugs for cancer and other diseases worldwide |
Nurix Inc. |
Gilead Sciences Inc. |
$2,345.00 |
6/19/19 |
Merck and Oncolytics to conduct a phase II clinical study of pelareorep in combination with paclitaxel and avelumab against metastatic breast cancer |
Oncolytics Biotech Inc. |
Merck KGaA |
Payment unspecified |
6/5/19 |
Oncotherapy to develop, manufacture and sell Thyas's T cell with peptide vaccine worldwide for cancer |
Oncotherapy Science Inc. |
Thyas Co. Ltd. |
Payment unspecified |
6/18/19 |
Agropur to manufacture, supply and distribute Optibiotix's Slimbiome for weight loss in the U.S., Canada and Mexico |
Optibiotix Health plc |
Agropur Cooperative |
Payment unspecified |
6/24/19 |
Denovo Biopharma to develop, manufacture and commercialize Orion's ORM-12741 against neuropsyciatric indications like Alzheimer's disease, schizophrenia and depression worldwide |
Orion Corp. |
Denovo Biopharma LLC |
Payment unspecified |
6/18/19 |
Oxford Biomedica and Santen to research and develop gene therapy products plus to generate preclinical proof of concept against inherited retinal disease with OXB's lentiviral vectors |
Oxford Biomedica plc |
Santen Pharmaceutical Co. Ltd. |
Payment unspecified |
6/26/19 |
Particle Sciences to manufacture Hoth Therapeutics' Biolexa therapeutic for atopic dermatitis |
Particle Sciences Inc. |
Hoth Therapeutics Inc. |
Payment Unspecified |
6/10/19 |
Patheon U.K. to provide Savara manufacturing services for drug products specified from time to time |
Patheon U.K. Ltd. |
Savara Inc. |
Payment unspecified |
6/27/19 |
Pharmain to investigate drug carrier and delivery protected graft co-polymer technology in combination with Peptidream's peptide discovery and development programs |
Pharmain Ltd. |
Peptidream Inc. |
Payment unspecified |
6/5/19 |
Effrx to register and commercialize Pharmaxis's Bronchitol for cystic fibrosis in Switzerland |
Pharmaxis Ltd. |
Effrx Pharmaceuticals SA |
Payment unspecified |
6/13/19 |
C4X Discovery to integrate Taxonomy3 technology with Phoremost's siteseeker screening platform to develop therapies against Parkinson's disease |
Phoremost Ltd |
C4X Discovery Holdings plc |
Payment unspecified |
6/25/19 |
Bicycle Therapeutics to award contract to Physiomics to support immune-oncology program |
Physiomics plc |
Bicycle Therapeutics Ltd. |
Payment unspecified |
6/28/19 |
Odyssey and Prevacus to sign a letter of intent to form joint venture for development of neurosteroid against orphan disorders |
Prevacus Inc. |
Odyssey Group International Inc. |
Payment unspecified |
6/4/19 |
Purec to develop and manufacture mesenchymal stem cell regenerative medicine products to Fujifilm for treatment of congenital osteogenesis imperfecta |
Purec Co. Ltd. |
Fujifilm Corp. |
Payment unspecified |
6/19/19 |
Ono Pharmaceutical to develop and commercialize Rafael Pharmaceuticals' CPI-613 in Japan, South Korea, Taiwan and Association of Southeast Asian Nations countries |
Rafael Pharmaceuticals Inc. |
Ono Pharmaceutical Co. Ltd. |
$163.20 |
6/25/19 |
Leidos Biomedical to award subcontract to Reaction Biology to develop drugs against colorectal cancer using surface plasmon resonance technology |
Reaction Biology Corp. |
Leidos Biomedical Research Inc. |
Payment unspecified |
6/4/19 |
Regis Technologies to manufacture Hoth Therapeutics' Biolexa therapeutic for atopic dermatitis |
Regis Technologies Inc. |
Hoth Therapeutics Inc. |
Payment Unspecified |
6/10/19 |
Resolution Bioscience and Janssen to investigate a Resolution HRD liquid biopsy assay as a companion diagnostic for niraparib against metastatic castration-resistant prostate cancer |
Resolution Bioscience Inc. |
Janssen Research & Development LLC |
Payment unspecified |
6/19/19 |
Samsung Biologics to manufacture U.S. biopharmaceutical's early-stage asset |
Samsung Biologics Co. Ltd. |
Undisclosed U.S. biopharmaceutical |
$301.00 |
6/4/19 |
Seven and Eight Biopharmaceuticals and Roche to evaluate combination of BDB-001 with atezolizumab against solid tumors |
Seven and Eight Biopharmaceuticals Inc. |
Roche Holding AG |
Payment unspecified |
6/19/19 |
Shanghai Huaaotai Biological to transfer HOT-1010 technology rights to Shanghai Junshi |
Shanghai Huaota Biopharma Co. Ltd. |
Shanghai Junshi Biosciences Co. Ltd. |
$13.33 |
6/24/19 |
EOC Pharma to develop, manufacture and market Shionogi's epertinib in China, Hong Kong and Macau for breast cancer |
Shionogi & Co. Ltd. |
EOC Pharma Ltd. |
Payment unspecified |
6/24/19 |
Eddingpharm to commercialize Shionogi's lusutrombopag for thrombocytopenia in China, Hong Kong, and Macau |
Shionogi & Co. Ltd. |
Eddingpharm Inc. |
Payment unspecified |
6/24/19 |
Sorrento Therapeutics and Lifetech Scientific to form joint venture Shenzhen Yunma Biotechnology to commercialize water-soluble cannabinoid formulation technologies for multiple indications in Asia, excluding Japan |
Sorrento Therapeutics Inc. |
Lifetech Scientific Inc. |
Payment unspecified |
6/4/19 |
GSK to conduct phase Ib study to evaluate Springworks' nirogacest in combination with belantamab mafodotin against relapsed or refractory multiple myeloma |
Springworks Therapeutics Inc. |
Glaxosmithkline plc |
Payment unspecified |
6/27/19 |
Starpharma to develop dendrimer enhanced product version of AstraZeneca's undisclosed oncology product |
Starpharma Holdings Ltd. |
Astrazeneca plc |
$5.00 |
6/3/19 |
Straub Medical to conduct pilot study of Emmaus' L-glutamine against type II diabetes |
Straub Medical Ag |
Emmaus Medical Inc. |
Payment unspecified |
6/24/19 |
Suda Pharmaceuticals to develop and supply oral spray cannabinoid derivatives to Cann Pharmaceutical for epilepsy, melanoma and motion sickness worldwide |
Suda Pharmaceuticals Ltd. |
Cann Pharmaceutical Australia Ltd |
$1.50 |
6/5/19 |
CMS to develop and commercialize Sun Pharma's Cyclosporine A for dry eye disease in greater China including mainland China, Hong Kong, Macao and Taiwan |
Sun Pharmaceutical Industries Ltd. |
China Medical System Holdings Ltd. |
Payment unspecified |
6/27/19 |
China Medical System to develop and commercialize Sun Pharmaceutical's Tildrakizumab against psoriasis and psoriatic arthritis in greater China |
Sun Pharmaceutical Industries Ltd. |
China Medical System Holdings Ltd. |
Payment unspecified |
6/27/19 |
TLC to develop and manufacture liposomal formulation of Birdie Biopharmaceuticals' TLR7/8 using Nanox technology for cancer |
Taiwan Liposome Co. |
Birdie Biopharmaceuticals Inc. |
$49.00 |
6/25/19 |
Tedor Pharma to manufacture Adial's AD-04 |
Tedor Pharma Inc. |
Adial Pharmaceuticals LLC |
Payment unspecified |
6/6/19 |
Tessa Therapeutics and CSGKC to form a joint venture to develop cell therapies for cancer in China |
Tessa Therapeutics Pte Ltd. |
Sino-Singapore Guangzhou Knowledge City Investment and Development Co. Ltd. |
$120.00 |
6/12/19 |
Bristol-Myers Squibb to develop liver tissue model for screening the toxicity of drugs using Draper's human organ systems platform |
The Charles Stark Draper Laboratory Inc. |
Bristol-Myers Squibb Co. |
Payment unspecified |
6/27/19 |
Theramex to commercialize Therapeuticsmd's Bijuva and Imvexxy for menopause worldwide, excluding the U.S., Canada and Israel |
Therapeuticsmd Inc. |
Theramex |
$49.39 |
6/7/19 |
Theravance Biopharma and Mylan expanded the agreement for nebulized revefenacin to include China and certain adjacent territories |
Theravance Biopharma Ireland Ltd. |
Mylan NV |
$72.50 |
6/17/19 |
Tilt Biotherapeutics and Merck to assess combination of TILT-123 with Avelumab for solid tumors |
Tilt Biotherapeutics Ltd. |
Merck KGaA |
Payment unspecified |
6/25/19 |
TOT Biopharm and Shanghai Junshi to develop a combination therapy by combining TAB-008 & JS-001 against hepatocellular carcinoma |
TOT Biopharm Co. Ltd. |
Shanghai Junshi Biosciences Co. Ltd. |
Payment unspecified |
6/19/19 |
Ultragenyx Pharmaceutical and Arcturus Therapeutics expanded the 2015 collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets |
Ultragenyx Pharmaceutical Inc. |
Arcturus Therapeutics Holdings Inc. |
$39.60 |
6/20/19 |
TTY Biopharm and an undisclosed international company to develop generic version of octreotide LAR in overseas markets |
Undisclosed |
TTY Biopharm Co. Ltd. |
$5.00 |
6/25/19 |
Pfizer's Centers for Therapeutic Innovation and Uniquest to develop drug candidates for cancer in Australia |
Uniquest Pty Ltd. |
Pfizer Pty Ltd. (Australia) |
Payment unspecified |
6/3/19 |
Astellas to use Vect Horus' Vectrans technology to transport the antibody to the brain for central nervous system diseases |
Vect-Horus |
Astellas Pharma Inc. |
Payment unspecified |
6/4/19 |
Vernalis and Phoremost to develop therapeutics for cancer |
Vernalis Research Ltd. |
Phoremost Ltd. |
Payment unspecified |
6/12/19 |
Sanofi Genzyme to acquire option to develop and commercialize Voyager's selected adeno-associated virus capsids for up to two non-central nervous system indications worldwide |
Voyager Therapeutics Inc. |
Sanofi Genzyme |
$116.00 |
6/14/19 |
Sanofi Genzyme to return VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program to Voyager Therapeutics |
Voyager Therapeutics Inc. |
Sanofi Genzyme |
$20.00 |
6/18/19 |
Seraxis and Wake Forest Baptist Health to further develop SR-01 for diabetes |
Wake Forest Baptist Health |
Seraxis Inc. |
Payment unspecified |
6/19/19 |
Widetrial to provide Oncotelic's OT-101 under expanded access program for pancreatic cancer, advanced melanoma, colorectal cancer and glioblastoma |
Widetrial Inc. |
Oncotelic Inc. |
Payment unspecified |
6/3/19 |
Willow Biosciences and Noramco to jointly develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol |
Willow Biosciences Inc. |
Noramco Inc. |
Payment unspecified |
6/4/19 |
Stada Arzneimittel to develop and commercialize Xbrane's Spherotide for cancer in Europe |
Xbrane Biopharma AB |
Stada Arzneimittel AG |
Payment unspecified |
6/4/19 |
Y-Biologics and Genosco to test combination of immune checkpoint inhibitors and small-molecule cancer drugs |
Y-Biologics Inc. |
Genosco |
Payment unspecified |
6/3/19 |
Yposkesi to manufacture and produce Axovant's cGMP adeno-associated virus to advance gene therapy programs |
Yposkesi SAS |
Axovant Gene Therapies Ltd. |
Payment unspecified |
6/21/19 |
Yposkesi to manufacture lentiviral vectors for Servier to use in allogenic chimeric antigen receptor T cell technology development for cancer |
Yposkesi SAS |
Servier SA |
Payment unspecified |
6/5/19 |
July | ||||
Alnylam and 23andme to offer 23andme health + ancestry kits to relatives of customers with TTR-related hereditary amyloidosis |
23andme Inc. |
Alnylam Pharmaceuticals Inc. |
Payment unspecified |
7/16/19 |
3P to manufacture Toleranzia's TOL-2 for preclinical and clinical studies in myasthenia gravis |
3P Biopharmaceuticlas SL |
Toleranzia AB |
Payment unspecified |
7/2/19 |
AD Pharma to fund the development and commercialization of Acura Pharmaceuticals' LTX-03 against pain |
Acura Pharmaceuticals Inc. |
Abuse Deterrent Pharmaceutical LLC |
$21.30 |
7/2/19 |
Adamis and Kaleo to settle patent infringement of Adamis' Zimhi naloxone product and Symjepi trademark |
Adamis Pharmaceuticals Corp. |
Kaleo Inc. |
Payment unspecified |
7/18/19 |
Innovation to develop and commercialize Alfasigma's brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis |
Alfasigma SpA |
Innovation Pharmaceuticals Inc. |
$24.00 |
7/22/19 |
Aptus Clinical to design phase I/II clinical study for Valirx's VAL-301 for endometriosis |
Aptus Clinical Ltd. |
Valirx plc |
Payment unspecified |
7/4/19 |
Arbutus to sell its remaining royalty interest of Onpattro for hereditary transthyretin-mediated amyloidosis to Omers |
Arbutus Biopharma Corp. |
Omers |
$20.00 |
7/2/19 |
Avid Bioservices to provide manufacturing services to undisclosed pharmaceutical company to develop drugs |
Avid Bioservices Inc. |
Undisclosed |
Payment unspecified |
7/8/19 |
KISS Industries to formulate and sell Axim Biotechnologies' chewing gum containing cannabinoids in the U.S. and Mexico |
Axim Biotechnologies Inc. |
Kiss Industries |
Payment unspecified |
7/9/19 |
Be The Match to support clinical trials of Tmunity's T cell immunotherapies against solid tumor and hematological cancer using Matchsource supply chain software |
Be The Match Biotherapies |
Tmunity Therapeutics Inc. |
Payment unspecified |
7/9/19 |
Genmab to develop and commercialize Blink's CD47 antibodies using Duobody platform against cancer |
Blink Biomedical SAS |
Genmab A/S |
$202.25 |
7/12/19 |
Brammer Biopharmaceuticals to manufacture Amicus' intrathecal adeno-associated virus Batten disease gene therapy programs |
Brammer Biopharmaceuticals LLC |
Amicus Therapeutics Inc. |
Payment unspecified |
7/1/19 |
Boehringer and Bridge to develop BBT-877 against fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis worldwide |
Bridge Biotherapeutics Inc. |
Boehringer Ingelheim International GmbH |
$1,286.52 |
7/18/19 |
Ra Pharmaceuticals to develop and commercialize zilucoplan long acting formulation using Camurus's Fluidcrystal technology worldwide |
Camurus AB |
Ra Pharmaceuticals Inc. |
$71.50 |
7/16/19 |
Cediprof to distribute Lannett's Levothyroxine Sodium tablets in the U.S., excluding Puerto Rico and the Virgin Islands |
Cediprof Inc. |
Lannett Co. Inc. |
$20.00 |
7/3/19 |
Celltrion and Nan Fung to establish a joint venture, Vcell Healthcare Ltd. to develop and commercialize CT-P13, CT-P10 and CT-P6 in China |
Celltrion Inc. |
Nan Fung Group Holdings Ltd. |
Payment unspecified |
7/18/19 |
Cipla EU and Jiangsu Acebright to set up a joint venture in China to manufacture local respiratory products |
Cipla Europe NV |
Jiangsu Acebright Pharmaceutical Co. Ltd. |
Unknown |
7/16/19 |
Aura Biosciences to use Clearside's Suprachoroidal space microinjector for delivery of therapeutics against ocular cancers worldwide |
Clearside Biomedical Inc. |
Aura Biosciences Inc. |
Payment unspecified |
7/9/19 |
Clover Therapeutics and Genentech to conduct research on genetics of ocular diseases |
Clover Therapeutics |
Genentech Inc. |
Payment unspecified |
7/10/19 |
Convelo and Genentech to discover and develop remyelinating therapies for neurological disorders including multiple sclerosis worldwide |
Convelo Therapeutics Inc. |
Genentech Inc. |
Payment unspecified |
7/16/19 |
CVS Caremark to distribute Titan Pharmaceuticals' Probuphine implant for opioid use disorder in the U.S. |
CVS Caremark |
Titan Pharmaceuticals Inc. |
Payment unspecified |
7/9/19 |
Upsher-Smith acquires assets of Zembrace and Tosymra from Dr. Reddy's in the U.S. |
Dr. Reddy's Laboratories Ltd. |
Upsher-Smith Laboratories Inc. |
$110.50 |
7/23/19 |
Gilead Sciences to develop and commercialize Durect's HIV product using Saber technology |
Durect Corp. |
Gilead Sciences Inc. |
$320.00 |
7/22/19 |
Confo Therapeutics and Dynabind to discover undisclosed G protein-coupled receptor modulating compounds worldwide |
Dynabind GmbH |
Confo Therapeutics NV |
Payment unspecified |
7/3/19 |
Egeen to conduct clinical phase IIb trial of Cyxone's rabeximod against rheumatoid arthritis in select Eastern European countries |
Egeen Inc. |
Cyxone AB |
Payment unspecified |
7/19/19 |
Ono to develop, manufacture and commercialize Forty's 5F9 and other antibodies against CD47 in Japan, South Korea, Taiwan and the ASEAN countries |
Forty Seven Inc. |
Ono Pharmaceutical Co. Ltd. |
$119.80 |
7/10/19 |
Astellas to develop and commercialize Frequency's FX-322 for sensorineural hearing loss worldwide excluding the U.S. |
Frequency Therapeutics |
Astellas Pharma Inc. |
$625.00 |
7/17/19 |
Dionymed to distribute Fruit Slabs' cannabis portfolio against pain, anxiety and sleep disorder in Central Valley and Northern California |
Fruit Slabs |
Dionymed Brands Inc. |
Payment unspecified |
7/11/19 |
Gilead to develop Galapagos's GLPG-1690 for idiopathic pulmonary fibrosis, with an option to develop GLPG-1972 in the U.S. for osteoarthritis and other clinical programs outside of Europe |
Galapagos NV |
Gilead Sciences Inc. |
$6,525.00 |
7/14/19 |
Avalon and GE Healthcare to accelerate the standardization, automation and bio-production for Chimeric antigen receptor T cell therapy, cellular immunotherapy and exosomes/extracellular vesicles based regenerative therapeutics |
GE Healthcare |
Avalon Globocare Corp. |
Payment unspecified |
7/22/19 |
Yaopharma to acquire all stock rights of Glaxosmithkline's lamivudine tablets against infections |
Glaxosmithkline plc |
Yaopharma Co. Ltd. |
$36.64 |
7/8/19 |
Torrent to comarket Glenmark's remogliflozin etabonate for type 2 diabetes in India |
Glenmark Pharmaceuticals Ltd. |
Torrent Pharmaceuticals Ltd. |
Payment Unspecified |
7/11/19 |
Ecobrands to distribute Green Gorilla's organic hemp cannabidiol products in Europe, Scandinavia |
Green Gorilla |
Ecobrands AS |
$10.00 |
7/17/19 |
Grupo RPH to manufacture and distribute Telix's TLX591-Cdx for prostate cancer in Brazil |
Grupo RPH Radiopharmacus SA |
Telix Pharmaceuticals Ltd. |
Payment unspecified |
7/3/19 |
Wuxi Pharmatech to develop Guangdong Zhongsheng Pharmaceutical's ZSYM-011 for the treatment of diabetic macular edema |
Guangdong Zhongsheng Pharmaceutical Co. Ltd. |
Wuxi Pharmatech (Cayman) Inc. |
Payment unspecified |
7/1/19 |
Treaigui and Moon Biotech to discover, develop and promote microecological drugs for ulcerative colitis |
Guangzhou Treatgut Biotech |
Guangzhou Moon biotech |
Payment unspecified |
7/16/19 |
Daewoong to co-promote Lundbeck's Ebixa for Alzheimer disease in Korea |
H Lundbeck A/S |
Daewoong Pharmaceutical Co. Ltd. |
Payment unspecified |
7/12/19 |
Hikma to manufacture and supply 14 essential generic medicines for Civica Rx in the U.S. |
Hikma Pharmaceuticals plc |
Civica Inc. |
Payment unspecified |
7/23/19 |
Roche to use Imaginab's minibody CD8 T-cell imaging agent for cancer clinical trials |
Imaginab Inc. |
Roche Holding AG |
Payment unspecified |
7/9/19 |
Immunoprecise Antibodies and Entos Pharmaceuticals to antibody against an immuno-oncology target using B cell select platform |
Immunoprecise Antibodies Ltd. |
Entos Pharmaceuticals Inc. |
Payment unspecified |
7/15/19 |
Incyte and Zai Lab to develop and commercialize INCMGA-0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan |
Incyte Corp. |
Zai Lab Ltd. |
$77.50 |
7/2/19 |
Aum Biosciences to develop and commercialize Inflection Biosciences' IBL-302 for cancers worldwide |
Inflection Biosciences Ltd. |
Aum Biosciences Pte. Ltd. |
Payment unspecified |
7/17/19 |
Inscopix and Biogen to research and develop therapies for chronic pain |
Inscopix |
Biogen Inc. |
Payment unspecified |
7/15/19 |
Glaukos to research, develop, manufacture and commercialize Intratus' drug delivery platform for dry eye disease, glaucoma and other corneal disorders worldwide |
Intratus Inc. |
Biogen Inc. |
Payment unspecified |
7/22/19 |
Celsius to identify the predictive response biomarkers in Janssen's Vega study using single cell genomics and machine learning platform |
Janssen Biotech Inc. |
Celsius Therapeutics Inc. |
Payment unspecified |
7/9/19 |
Celgene to develop and commercialize Jounce' JTX-8064 for cancer worldwide |
Jounce Therapeutics Inc. |
Celgene Corp. |
$530.00 |
7/22/19 |
Onkure to develop Kdac Therapeutics' OKI-422 against cancer |
Kdac Therapeutics Inc. |
Onkure Inc. |
Payment unspecified |
7/23/19 |
LGC to manufacture Aptahem's Apta-1 for concluding toxicological studies |
LGC Group |
Aptahem AB |
Payment unspecified |
7/4/19 |
SQ Innovation to use Ligand's captisol technology to develop captisol-enabled furosemide formulation for edema in heart failure patients worldwide |
Ligand Pharmaceuticals Inc. |
SQ Innovation AG |
Payment unspecified |
7/8/19 |
Gilead and Lyndra to develop and commercialize ultra-long-acting oral human immunodeficiency virus therapies |
Lyndra Therapeutics Inc. |
Gilead Sciences Inc. |
Payment unspecified |
7/9/19 |
Lysando and Aicuris to develop Artilysin based drugs for bacterial infections including hospital-acquired pneumonia, sepsis and cystic fibrosis |
Lysando AG |
Aicuris Anti-infective Cures GmbH |
Payment unspecified |
7/9/19 |
Puretech Health acquires LYT-100 for the treatment of lymphatic and immunofibrotic diseases, including lymphedema from Lyticon |
Lyticon LLC |
Puretech Health plc |
Payment unspecified |
7/17/19 |
I-Mab to develop and commercialize Macrogenics' enoblituzumab for cancer in mainland China, Hong Kong, Macau and Taiwan |
Macrogenics Inc. |
I-Mab Biopharma (Shanghai) Co. Ltd. |
$150.00 |
7/10/19 |
Mercachem to provide services to Gotham Therapeutics for accelerated hit generation and hit-to-lead expansion for epitranscriptomic target space |
Mercachem Holding BV |
Gotham Therapeutics Corp. |
Payment unspecified |
7/17/19 |
Novartis and Mirati to evaluate the combination of MRTX-849 and TNO-155 against solid tumors |
Mirati Therapeutics Inc. |
Novartis AG |
Payment unspecified |
7/9/19 |
SCM and Mitoimmune to develop therapies against intractable, inflammatory, and rare diseases using cMSC and mitochondria technology |
Mitoimmune Therapeutics Inc. |
SCM Lifescience Ltd. |
Payment unspecified |
7/11/19 |
Evotec acquired assets from Ncardia to advance induced pluripotent stem cells platform |
Ncardia AG |
Evotec SE |
Payment unspecified |
7/24/19 |
Lannett to distribute Neolpharma's generic levothyroxine sodium tablets for thyroid deficiency in the U.S. |
Neolpharma Group |
Lannett Co. Inc. |
$20.00 |
7/8/19 |
Ocumension to develop and commercialize Nicox's NCX-4251 for blepharitis in mainland China, Hong Kong, Macau and Taiwan |
Nicox SA |
Ocumension Therapeutics |
$11.57 |
7/2/19 |
Nimbus expanded the collaboration with Celgene to include Hematopoietic Progenitor Kinase 1 (HPK1) program against oncology |
Nimbus Therapeutics Inc. |
Celgene Corp. |
Payment unspecified |
7/9/19 |
Nosopharm and Evotec to advance development of NOSO-502 for enterobacteriace infection and NOSO-2G for the treatment of complicated urinary tract infections and complicated intra-abdominal infections |
Nosopharm SAS |
Evotec SE |
Payment unspecified |
7/3/19 |
Recordati to acquire Novartis' Signifor, Signifor LAR and LCI-699 for Cushing's disease and acromegaly |
Novartis AG |
Recordati SpA |
$390.00 |
7/12/19 |
Gilead to develop and commercialize Novartis' three preclinical programs and agents against three undisclosed targets for human rhinovirus, influenza and herpes viruses worldwide |
Novartis AG |
Gilead Sciences Inc. |
$291.00 |
7/19/19 |
Pepdesign to use Numaferm's technology platform for manufacturing diabetes and obesity drugs |
Numaferm GmbH |
Pepdesign SIA |
Payment unspecified |
7/22/19 |
Mundipharma to commercialize Orexo's Zubsolv (buprenorphine/naloxone) for the treatment of opioid dependence in Australia and New Zealand |
Orexo AB |
Mundipharma Pty Ltd. |
Payment unspecified |
7/10/19 |
Desitin to distribute Orphelia's Kigabeq for infantile spasms in Germany |
Orphelia Pharma SA |
Desitin Arzneimittel GmbH |
Payment unspecified |
7/16/19 |
Aevi Genomic Medicine to develop and commercialize OSI Pharmaceuticals' OSI-027 for congenital lymphatic malformations worldwide |
OSI Pharmaceuticals Inc. |
Aevi Genomic Medicine Inc. |
$0.50 |
7/15/19 |
Paragon Gene Therapy to provide development and manufacturing services for Avexis' Zolgensma for spinal muscular atrophy |
Paragon Bioservices Inc. |
Avexis Inc. |
Payment unspecified |
7/16/19 |
Paragon Gene Therapy to provide clinical manufacturing capabilities and capacity for Amicus' multiple active preclinical lysosomal disorder programs |
Paragon Gene Therapy |
Amicus Therapeutics Inc. |
Payment unspecified |
7/2/19 |
Peptidream to use peptide discovery platform system technology for the identification of novel macrocyclic/constrained peptides for use as peptide-drug conjugates against multiple targets of interest selected by Novartis |
Peptidream Inc. |
Novartis AG |
Payment unspecified |
7/1/19 |
Asieris Meditech to develop and commercialize Photocure's Cevira for human papillomavirus induced cervical precancerous lesions worldwide |
Photocure ASA |
Asieris Pharmaceuticals Co. Ltd. |
$250.00 |
7/1/19 |
Mundipharma to distribute, market and sell Prestige Biopharma's Tuznue in western European markets, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria |
Prestige Biopharma |
Mundipharma International Corp. Ltd. |
Payment unspecified |
7/2/19 |
Pharmapark to commercialize Prestige Biopharma's trastuzumab biosimilar in the Russian Federation |
Prestige Biopharma Pte. Ltd. |
Pharmapark LLC |
Payment unspecified |
7/8/19 |
Kappa to use Probiotix' LPLDL to address cardiovascular health in the 27 countries, largely in Europe including Russia and Singapore |
Probiotix Health Ltd. |
Kappa Bioscience AS |
Payment unspecified |
7/1/19 |
Tenshindo to use Probiotix' LPLDL to address cardiovascular health in Japan |
Probiotix Health Ltd. |
Tenshindo Inc. |
Payment unspecified |
7/3/19 |
Pro Med to distribute Mobidiag's Amplidiag and Novodiag in African countries including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya and Uganda |
Promed Diagnostics Ltd. |
Mobidiag Oy |
Payment unspecified |
7/1/19 |
Jazz Pharmaceuticals acquires Redx Pharma's pan-RAF inhibitor program for treatment of cancer |
Redx Pharma plc |
Jazz Pharmaceuticals plc |
$206.50 |
7/10/19 |
Resonance Health to conduct clinical trial to U.S. Nasdaq-listed pharmaceutical company |
Resonance Health Ltd. |
U.S. Nasdaq-listed pharmaceutical company |
$1.00 |
7/19/19 |
Avion to develop and commercialize Romeg's Gloperba for gout in the U.S. |
Romeg Therapeutics LLC |
Avion Pharmaceuticals LLC |
Payment unspecified |
7/16/19 |
Myokardia re-acquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi SA for $50M upfront, with an additional $30M payable to Sanofi by June 30, 2020. |
Sanofi SA |
Myokardia Inc. |
$80.00 |
7/22/19 |
Servier Australia and Biocurate to sign memorandum of understanding to accelerate discovery of therapeutics and drugs |
Servier Laboratories (Australia) Pty Ltd. |
Biocurate Pty Ltd. |
Payment unspecified |
7/15/19 |
Kurve Technology and Seurat Therapeutics to use drug delivery device for IGF-1 for migraine prevention in adults |
Seurat Therapeutics Inc. |
Kurve Technology Inc. |
Payment unspecified |
7/2/19 |
AMR Centre to research, develop and manufacture Shionogi's COT-143 against Pseudomonas aeruginosa infection worldwide |
Shionogi & Co. Ltd. |
AMR Centre Ltd. |
Payment unspecified |
7/22/19 |
Mallinckrodt to develop and commercialize Silence's SLN-500 and with an option to up to two RNAi therapeutics against autoimmune diseases worldwide |
Silence Therapeutics plc |
Mallinckrodt plc |
$2,104.00 |
7/18/19 |
Genentech and Skyhawk to discover, develop and commercialize small molecules for oncology and neurological diseases using Skystar technology platform worldwide |
Skyhawk Therapeutics Inc. |
Genentech Inc. |
$2,000.00 |
7/16/19 |
Merck and Skyhawk to discover, develop and commercialize small molecules for neurological diseases and cancers using Skystar technology platform worldwide |
Skyhawk Therapeutics Inc. |
Merck & Co. Inc. |
$600.00 |
7/8/19 |
Alfasigma USA acquires Sloan Pharma's Zelnorm for irritable bowel syndrome with constipation |
Sloan Pharma |
Alfasigma USA Inc. |
Payment unspecified |
7/8/19 |
Sosei Heptares and Genentech to discover, develop and commercialize G protein-coupled receptor modulating small molecules and/or biologics for range of diseases worldwide |
Sosei Heptares |
Genentech Inc. |
$1,026.00 |
7/16/19 |
Spectronrx to develop, manufacture and supply Y-mabs' radiolabelled omburtamab against central nervous system tumor |
Spectronrx |
Y-mabs Therapeutics Inc. |
Payment unspecified |
7/1/19 |
Abzena to use Synaffix's Glycoconnect and Hydraspace technologies to develop therapies |
Synaffix BV |
Abzena plc |
Payment unspecified |
7/23/19 |
Teva to launch Hanmi's Hialuma for pain in osteoarthritis in the U.S. |
Teva Pharmaceutical Industries Ltd. |
Hanmi Pharmaceutical Co. Ltd. |
Payment unspecified |
7/2/19 |
Undisclosed U.S. based CMO to manufacture Leaf Pharmaceuticals' LEAF-1404 for cancer |
Undisclosed |
Leaf Pharmaceuticals |
Payment unspecified |
7/11/19 |
Valeo Pharma to register, distribute and market an undisclosed pharmaceutical manufacturer's low molecular weight heparin biosimilar against deep vein thrombosis and pulmonary embolism in Canada |
Undisclosed international pharmaceutical manufacturer |
Valeo Pharma Inc. |
Payment unspecified |
7/8/19 |
Vaxart and Janssen to evaluate oral vaccine platform for universal influenza vaccine program worldwide |
Vaxart Inc. |
Janssen Vaccines & Prevention BV |
Payment unspecified |
7/9/19 |
Vgxi to manufacture GT-EPIC based personalized cancer therapeutics to Geneos |
Vgxi Inc. |
Geneos Therapeutics Inc. |
Payment unspecified |
7/22/19 |
Lloyd to manufacture Viriom's Elpida and other drugs against human immunodeficiency virus infection in Indonesia |
Viriom Inc. |
Lloyd Laboratories Inc. |
Payment unspecified |
7/2/19 |
Morphosys to acquire option to develop and commercialize Vivoryon's small molecule small-molecule glutaminyl-peptide cyclotransferase-like inhibitors including PQ-912 for cancer worldwide |
Vivoryon Therapeutics AG |
Morphosys AG |
$16.85 |
7/8/19 |
Abbisko Therapeutics to develop and commercialize X4 Pharmaceuticals' mavorixafor for oncology in greater China |
X4 Pharmaceuticals Inc. |
Abbisko Therapeutics Co. Ltd. |
Payment unspecified |
7/16/19 |
Boehringer Ingelheim and Yuhan to develop GLP1R/FGF21R agonist for the treatment of nonalcoholic steatohepatitis and related liver diseases |
Yuhan Corp. |
Boehringer Ingelheim International GmbH |
$870.00 |
7/1/19 |
Celgene selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the 2014 Azymetric collaboration and licensing agreement with Zymeworks |
Zymeworks Inc. |
Celgene Corp. |
$7.50 |
7/17/19 |
|
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. | ||||